NCT03462927 - A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 8, 2018

Primary Completion Date

August 4, 2018

Study Completion Date

August 4, 2018

Conditions

Psoriasis Vulgaris

Interventions

DRUG

MC2-01 Cream

MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)

DRUG

CAL/BDP combination

Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)

Trial Locations (1)

Lenus Research and Medical Group, Sweetwater